Pharma 54: Protozoal Infections - One Kingdom, Many Battles

This episode expands antimicrobial thinking beyond malaria to the diverse world of protozoal infections-amebiasis, giardiasis, trichomoniasis, leishmaniasis, trypanosomiasis, and beyond. The unifying lesson is diversity: protozoa share a kingdom, not a strategy. We explore metabolic vulnerabilities, tissue tropism, intracellular sanctuaries, and host–parasite dynamics to show why drugs that cure one protozoal disease may be useless-or dangerous-in another. Pharmacology here is about specificity, staging, and clinical context.Key takeaways to sharpen judgement:* Diversity within similarity: why “protozoa” is not a therapeutic category.* Tissue matters: luminal vs invasive disease changes drug choice.* Metabolic targets: redox systems, DNA synthesis, and unique enzymes.* Toxicity trade-offs: narrow therapeutic windows and monitoring burden.* Strategy over speed: eradication, suppression, or control depending on disease. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe